Predict your next investment

Academic/University
stanford.edu

See what CB Insights has to offer

Investments

138

Portfolio Exits

52

Partners & Customers

10

Service Providers

1

About Stanford University

The Center for Integrated Systems is a partnership between Stanford University and member industrial firms. Founded in 1982, CIS fosters industry and academic research relationships that also yields world-class Ph.D. graduates in fields related to integrated systems."Integrated systems" refers to complex interactions across hardware and software at several levels of structure, and to semiconductor, electronics, and computer systems within the context of real-world applications. CIS research, Ph.D. fellowships, and information-exchange programs draw on the unique strengths of the University and industry to enhance the productivity and competitiveness of both sectors. Contact.

Stanford University Headquarter Location

California,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Stanford University

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Stanford University in 2 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

G

Game Changers 2018

20 items

Research containing Stanford University

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Stanford University in 1 CB Insights research brief, most recently on Nov 18, 2019.

Latest Stanford University News

Susan G. Komen Invests $21.7 Million in Research Focused on Improving Outcomes for Breast Cancer Patients

Jun 23, 2022

Susan G. Komen , the world’s leading breast cancer organization, is awarding $21.7 million to fund 48 new research projects at 26 distinguished academic medical institutions in the U.S. that are focused on improving patient outcomes – particularly for people with the most aggressive breast cancers, or who have experienced a recurrence or metastasis. With this investment, Komen is now supporting more than 152 active research projects representing more than $115 million in funding. “The investment we are announcing in a broad portfolio of cutting-edge research will help advance breast cancer care and improve outcomes for all people diagnosed with breast cancer, including underserved populations and those with few treatment options,” said Victoria Wolodzko Smart, SVP of Mission at Susan G. Komen. “With this investment, we’re supporting some of the top breast cancer researchers who share our mission and giving everyone impacted by breast cancer hope, as we move closer to the cures for breast cancers.” Of the total $21.7 million awarded: 79 percent supports research focused on the most aggressive breast cancers, metastasis and recurrence; 33 percent supports clinical trials; 20 percent supports research focused on eliminating breast cancer disparities; “We still have much to learn about aggressive breast cancers and breast cancers that recur and metastasize. This critical research investment from Susan G. Komen will help us unravel the biology of breast cancers to better understand how to prevent breast cancer recurrence and metastasis, and develop more treatment options, including new treatments for people living with metastatic breast cancer,” said Jennifer Pietenpol, Ph.D., Susan G. Komen Chief Scientific Advisor. Pietenpol also serves as the Benjamin F. Byrd, Jr. Professor of Oncology, Chief Scientific and Strategy Officer and Executive Vice President for Research at Vanderbilt University Medical Center. Komen Research Grants Julie Palmer, Sc.D., M.P.H., Boston University Jennifer Ligibel, M.D., FASCO, Dana-Farber Cancer Institute Nancy Lin, M.D., Dana-Farber Cancer Institute Kornelia Polyak, M.D., Ph.D., Dana-Farber Cancer Institute Sara Tolaney, M.D., M.P.H., Dana-Farber Cancer Institute Nikhil Wagle, M.D., Dana-Farber Cancer Institute Sunil Badve, M.D., FRCPath, Emory University School of Medicine Maria Sosa, Ph.D., Icahn School of Medicine at Mount Sinai Tarah Ballinger, M.D., Indiana University Pedram Razavi, M.D., Ph.D., Memorial Sloan Kettering Cancer Center Jorge Reis-Filho, M.D., Ph.D., FRCPath, Memorial Sloan Kettering Cancer Center Sohrab Shah, Ph.D., Memorial Sloan Kettering Cancer Center Lisa Coussens, Ph.D., Oregon Health & Science University Yibin Kang, Ph.D., Princeton University Hai Wang, Ph.D., Roswell Park Cancer Institute Christina Curtis, Ph.D., M.S., Stanford University School of Medicine Melinda Telli, M.D., Stanford University School of Medicine Allison Kurian, M.D., M.Sc., Stanford University School of Medicine Haruka Itakura, M.D., Ph.D., Stanford University School of Medicine Daniel Hollern, Ph.D., The Salk Institute for Biological Studies Reshma Jagsi, M.D., D.Phil., University of Michigan Melissa Troester, Ph.D., University of North Carolina at Chapel Hill Angela DeMichele, M.D., M.S.C.E., University of Pennsylvania Adrian Lee, Ph.D., University of Pittsburgh Steffi Oesterreich, Ph.D., University of Pittsburgh Alana Welm, Ph.D., University of Utah Huntsman Cancer Institute Amelie Ramirez, Dr.P.H., M.P.H., UT Health San Antonio Mariana Chavez MacGregor, M.D., M.Sc., FASCO, UT M.D. Anderson Cancer Center Sharon Giordano, M.D., M.P.H., FASCO, UT M.D. Anderson Cancer Center Srinivas Malladi, Ph.D., UT Southwestern Medical Center Tuya Pal, M.D., Vanderbilt University Medical Center Ben Ho Park, M.D., Ph.D., Vanderbilt University Medical Center Jennifer Pietenpol, Ph.D., Vanderbilt University Medical  Center Sonya Reid, M.D., Ph.D., Vanderbilt University Medical Center Cynthia Ma, M.D., Ph.D., Washington University Rulla Tamini, Sc.D., Weill Cornell College of Cornell University Mariya Rozenblit, M.D., Yale University Lajos Pusztai, M.D., D.Phil., Yale University Komen has invested more than $1 billion in breast cancer research in the 40 years since its founding, more than any other non-profit, and second only to the U.S. government. [Source(s): Susan G. Komen, EurekAlert] Share:

Stanford University Investments

138 Investments

Stanford University has made 138 investments. Their latest investment was in Jeeves as part of their Series C on March 3, 2022.

CBI Logo

Stanford University Investments Activity

investments chart

Stanford University Portfolio Exits

52 Portfolio Exits

Stanford University has 52 portfolio exits. Their latest portfolio exit was Amprius on May 12, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/12/2022

Acq - Pending

$99M

3

5/2/2022

Acquired

1

2/3/2022

Reverse Merger

$99M

3

3/10/2021

Acquired

Subscribe to see more

Subscribe to see more

10

2/16/2021

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/12/2022

5/2/2022

2/3/2022

3/10/2021

2/16/2021

Exit

Acq - Pending

Acquired

Reverse Merger

Acquired

Reverse Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

1

3

10

10

Stanford University Acquisitions

1 Acquisition

Stanford University acquired 1 company. Their latest acquisition was Spectrum Holobyte on August 01, 1992.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/1/1992

Growth Equity

$99M

$10.4M

Leveraged Buyout

1

Date

8/1/1992

Investment Stage

Growth Equity

Companies

Valuation

$99M

Total Funding

$10.4M

Note

Leveraged Buyout

Sources

1

Stanford University Partners & Customers

10 Partners and customers

Stanford University has 10 strategic partners and customers. Stanford University recently partnered with BenevolentAI on February 2, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

2/3/2022

Partner

United Kingdom

Please don’t use this sentence out of context

In this exciting collaboration between BenevolentAI and Stanford University , we address these two challenges : we have developed methods to extract signed , causal gene-gene relationships from text and then associate these relationships with a specific biological context to reconcile apparently contradictory facts .

1

1/21/2022

Partner

India

How this Gurugram-based English learning platform is getting children to read for pleasure

Launched in 2016 , Freadom equips children to learn to read in English in any country where it is an aspirational second language , via its state-of-the-art recommendation engine ; built-in collaboration with Stanford University to drive English language learning .

1

1/12/2022

Partner

United States

(Image credit: Courtesy CZ Biohub). Second cohort of CZ Biohub Investigators includes 33 Stanford faculty - Stanford Report

The Chan Zuckerberg Biohub is a Bay Area research collaboration between Stanford University , UC Berkeley and UCSF that aims to better understand the fundamentals of disease and develop new technologies that could lead to more actionable diagnostics and effective therapies .

1

12/16/2021

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

12/15/2021

Partner

Subscribe to see more

Subscribe to see more

10

Date

2/3/2022

1/21/2022

1/12/2022

12/16/2021

12/15/2021

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

United Kingdom

India

United States

United Kingdom

News Snippet

Please don’t use this sentence out of context

In this exciting collaboration between BenevolentAI and Stanford University , we address these two challenges : we have developed methods to extract signed , causal gene-gene relationships from text and then associate these relationships with a specific biological context to reconcile apparently contradictory facts .

How this Gurugram-based English learning platform is getting children to read for pleasure

Launched in 2016 , Freadom equips children to learn to read in English in any country where it is an aspirational second language , via its state-of-the-art recommendation engine ; built-in collaboration with Stanford University to drive English language learning .

(Image credit: Courtesy CZ Biohub). Second cohort of CZ Biohub Investigators includes 33 Stanford faculty - Stanford Report

The Chan Zuckerberg Biohub is a Bay Area research collaboration between Stanford University , UC Berkeley and UCSF that aims to better understand the fundamentals of disease and develop new technologies that could lead to more actionable diagnostics and effective therapies .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Stanford University Service Providers

1 Service Provider

Stanford University has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

Partnership data by VentureSource

Stanford University Team

20 Team Members

Stanford University has 20 team members, including current President, Alan Chiu.

Name

Work History

Title

Status

Khizer Khaderi

Founder

Current

Matt Rothe

Founder

Current

Alan Chiu

President

Current

Randy Livingston

Chief Financial Officer

Current

Brentan Alexander

Founder, President

Former

Name

Khizer Khaderi

Matt Rothe

Alan Chiu

Randy Livingston

Brentan Alexander

Work History

Title

Founder

Founder

President

Chief Financial Officer

Founder, President

Status

Current

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.